Journal Scans
Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Vandetanib for Metastatic Hereditary Medullary Thyroid Cancer
SA Wells Jr, JE Gosnell, RF Gagel, J Mole, D Pfister, JA Sosa, M Skinner, A Krebs, J Vasselli, M Schlumberger
20100011
2010 Jan 11
J Clin Oncol
Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
J Clin Oncol. 2010 Jan 11;[Epub Ahead of Print], SA Wells Jr, JE Gosnell, RF Gagel, J Mole, D Pfister, JA Sosa, M Skinner, A Krebs, J Vasselli, M Schlumberger
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Hereditary medullary thyroid cancer (MTC) occurs as 3 distinct inherited syndromes: familial MTC (FMTC), multiple endocrine neoplasia (MEN) type 2A (MEN2A), and MEN type 2B (MEN2B). Early treatment is associated with a 10-year survival rate of 70% to 80%, but 10-year survival rates fall to <50% in patients with distant metastases. Hereditary MTC is caused by germline mutations in the RET proto-oncogene. RET oncoproteins associated with MTC are highly sensitive to agents that inhibit wild-type RET...
